Biotech Values

[genisi]

Lots of perhaps in the current situation, but the fact is MNTA will have to supply additional data regarding immunogenicity via more animal or clinical trials. Either way, that means a delay of months to years.
While the market's reaction shows it doubts MNTA's characterization platform to ever satisfy the FDA, I find MNTA's platform very strong and accurate. I believe that MNTA will provide the required data and that M-enoxaparin will be approved eventually. This together with the value in their pipeline, made me buy some more on yesterday's additional downside.